演題詳細

一般口演 / Oral Session

一般口演 88 (Oral Session 88) :ITP・トロンボポエチン (ITP and Thrombopoietin)

print

日程
2013年10月13日(日)
時間
09:15 - 10:45
会場
第13会場 / Room No.13 (札幌市教育文化会館 3F 研修室301)
座長・司会
宮崎 浩二 (Koji Miyazaki):1
1:北里大学医学部 血液内科学
 
前へ戻る

rhTPO in combination with low dose rituximab in primary ITP : A multicenter prospective clinical trial

演題番号 : OS-3-84

Qin Ping:1、Xiao-yuan Dong:1、Miao Xu (徐 淼):1、Ming Hou:1、Jun Peng:1、Ji Ma:1、Hai Zhou:1

1:Department of Hematology, Qilu Hospital, Shandong University, China

 

Background: Adult primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by autoantibody-induced platelet destruction, which affects around 1 in 10,000 people. 25%-30% of the patients achieve no response to the conventional therapy. Aim: We reported 86 adult ITP patients treated with rhTPO in combination with LD RTX from 12 centers. This trial focused on exploring novel therapeutic strategies for ITP. We assessed response rates and safety of rhTPO combined with low-dose rituximab in primary ITP who had failed to response to glucocorticosteroids or relapsed. Method: rhTPO was given 300U/kg in the first 14 days, with 100mg qw rituximab weekly for 4 weeks. The dose frequency of rhTPO was adjusted according to the platelet counts. Primary outcomes include response (R), complete response (CR), no response (NR) and relapse. Secondary outcomes are listed as time to response and sustained time. This clinical trial was registered at http://clinicaltrials.gov as NCT01506414. Result: Response and complete responses were achieved in 26/86 (30.2%) and 35/86 (40.7%) patients respectively. In a follow-up of 3 months, 5 cases lost to follow-up, and 14/56 (25%) patients relapsed. Median time to response (or complete response) was 7 days (range 4-28 days). And the median sustained time was 79 days (range 3-86 days) in a total observation time of 90 days. Conclusion: Our findings suggest that combination of RTX and LD RTX in ITP improves response rate and yields shorter time to response compared with monotherapy of RTX in reports. Thus, combination therapy may represent an effective treatment option for glucocorticosteroids-resistant or relapsed patients.

前へ戻る